DAIZ Funding: How Much Did They Raise & Key Investors

How Much Did DAIZ Raise?
Funding & Key Investors

DAIZ, a pioneer in the development of advanced plant-based protein solutions, has successfully secured a significant capital injection, bringing its total funding to $47M. This latest financing round, which accounts for $47M, underscores the market's confidence in the company's proprietary Ochiai Germination Method (OGM). As the firm transitions into a major enterprise-level growth phase, this investment serves as a critical catalyst for scaling its food innovation pipeline and expanding its research into pharmaceutical applications.

The capital infusion reflects a strategic alignment with global leaders in food science and industrial chemistry, positioning DAIZ to accelerate the commercialization of its Miracle Meat technology. By leveraging this backing, the company is well-equipped to enhance its production capabilities and deepen its integration into the global supply chains of major food manufacturers, while simultaneously exploring the intersection of plant science and artificial intelligence for therapeutic discovery.

What is DAIZ?

DAIZ

Manufacturing

Food & Beverage

Business Services

DAIZ operates at the vanguard of food technology, utilizing its patented Ochiai Germination Method (OGM) to transform plant seeds into highly nutritional, functional raw materials. Unlike traditional meat alternatives that rely on additives, DAIZ’s Miracle Meat achieves superior texture and flavor profiles through biological optimization. Beyond the food sector, the company is pioneering a novel approach to drug discovery, utilizing OGM to explore secondary metabolites in organic molecules. This dual-market strategy—targeting both the rapidly expanding plant-based protein sector and the high-value pharmaceutical research space—establishes DAIZ as a unique entity in the biotechnology landscape, capable of bridging the gap between sustainable nutrition and advanced medical science.

How much funding has DAIZ raised?

DAIZ has raised a total of $47M across 1 funding round:

2023

Series C

$47M

Series C (2023): $47M with participation from Roquette Frères, Miyoshi Oil & Fat, The Kagoshima Bank, and Mitsubishi UFJ Capital

Key Investors in DAIZ

Roquette Frères

A global leader in plant-based ingredients and pharmaceutical solutions, Roquette focuses on sustainable nutrition and high-performance bio-based applications.

Miyoshi Oil & Fat

A specialized manufacturer of oil-based raw materials, providing essential fats and fatty acids for the food, pharmaceutical, and cosmetic industries.

Mitsubishi UFJ Capital

A prominent venture capital firm with extensive experience in the Japanese market, known for supporting high-growth companies through their IPO journey.

What's next for DAIZ?

Looking ahead, DAIZ is poised to leverage its recent capital to scale its OGM technology across international markets. The strategic roadmap includes deepening partnerships with global food manufacturers to integrate Miracle Meat into diverse product portfolios, thereby solidifying its market share in the meat-alternative industry. Simultaneously, the company is expected to intensify its R&D efforts in drug discovery, utilizing AI-driven analysis to unlock new chemical spaces for therapeutic research. By maintaining a focus on proprietary technology and high-impact applications, DAIZ is strategically positioned to navigate the complexities of the global food and biotech sectors, ensuring long-term value creation for its stakeholders and investors.

See full DAIZ company page

See More Financial Insights